Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2008
06/05/2008US20080131499 Method and composition for solubilising a biologically active compound with low water solubilty
06/05/2008US20080131498 liposome-encapsulated busulphan formulations for parenteral administration are provided, as well as such formulations furthermore comprising glutathione and/or at least one glutathione precursor and a process for manufacture of the preparations. The formulations are stable, have improved biodistribution
06/05/2008US20080131496 topical therapeutically effective amount of melatonin encapsulated in a liposome applied topically to an area of skin affected by immunologic response, radiation treatment induced dermatitis, acne, insect bite or other irritant stimulus such as sunburn in order to reduce itching.
06/05/2008US20080131494 Dermal Penetration enhancers and drug delivery systems involving same
06/05/2008US20080131492 treatment of certain neural disorders/diseases, such as Parkinson's disease and other motor disorders. One aspect of the invention relates to drug compositions and dosage forms comprising said drug composition. Another aspect of the invention relates to methods of manufacturing the drug compositions
06/05/2008US20080131490 Stabilized donepezil-containing patch preparation
06/05/2008US20080131486 Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid mmatrix of a two biodegradable polymer matrix
06/05/2008US20080131485 Extruding mixture of alpha-2 adrenergic receptor agonist (brimonidine) and biodegradable polylactide
06/05/2008US20080131484 Intraocular drug delivery systems
06/05/2008US20080131483 Enhancement of Drug Delivery to the Central Nervous System
06/05/2008US20080131482 Biocompatible intraocular implants include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix
06/05/2008US20080131481 Hypotensive lipid-containing biodegradable intraocular implants and related methods
06/05/2008US20080131475 Stenosis, restenosis; active agent polymer matrix coated stents; easy adaptation of required drug release rate
06/05/2008US20080131472 Sulfated Depolymerized Derivatives of Exopolysaccharides (Eps) from Mesophilic Marine Bacteria, Method for Preparing Same, and Uses Thereof in Tissue Regeneration
06/05/2008US20080131468 Microorganisms; isolated replicable recombinant DNA; transformed cells
06/05/2008US20080131446 Vaccine Composition
06/05/2008US20080131441 Methods of Using FOXP3 Levels to Predict the Outcome of Organs Undergoing Acute Rejection
06/05/2008US20080131439 Using anti-neutrophil cytoplasmic antibody (ANCA) as diagnostic indicator of gastrointestinal disorders
06/05/2008US20080131437 Using allelic variation in cell adhesion molecule (CD164) as tool in treatment and prevntion of skin, arthritic and gastrointestinal disorders
06/05/2008US20080131424 Method of treatment and agents useful for same
06/05/2008US20080131422 Brain protein specific immunoglobulin for use in diagnosis, prevention and treatment of alzheimer's disease
06/05/2008US20080131421 Neisserial antigens
06/05/2008US20080131420 Methods and compositions for treating mucosal inflammation
06/05/2008US20080131412 Isoflavone-containing composition
06/05/2008US20080131411 Using vector transformation comprising wildtype fkhsf gene as therapeutic in prevention and treatment of skin and kidney disorders
06/05/2008US20080131407 Differentiation of bone marrow cells into neuronal cells and uses therefor
06/05/2008US20080131401 Using starch mixture as carrier agent for localizing preferential probiotic organisms
06/05/2008US20080131398 Combination therapy for treatment of viral infections
06/05/2008US20080131386 A water-soluble divalent strontium cation in a suitable topical formulation vehicle; preferably, strontium nitrate, strontium chloride and strontium acetate; cosmetics; drugs soaps; detergents; antiallergens
06/05/2008US20080131385 Mixture of self-invertible inverse latex and a powder for cosmetic or pharmaceutical use; use as texturizer
06/05/2008US20080131382 For lightening tone
06/05/2008US20080131376 Carboranylporphyrins and uses thereof
06/05/2008US20080131375 Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
06/05/2008US20080131374 Pneumococcal vaccine and tumor necrosis factor antibodies; c-reactive protein; drug screening
06/05/2008US20080131372 Extruding mixture of alpha-2 adrenergic receptor agonist (brimonidine) and biodegradable polylactide
06/05/2008US20080131371 Oligonucleotide Non-Viral Delivery Systems
06/05/2008US20080131370 For prophylaxis or treatment of apoptosis or inflammation-associated disease, diabetes, or chronic obstructive pulmonary disease
06/05/2008US20080131366 Administering folate receptor alpha inducer comprising steroid receptor agent optionally with one or more histone deacetylase inhibitors to treat or diagnose a patient having a solid tumor; increases levels of receptors on cancer cell plasma membranes and in serum, ascites and cerebrospinal fluid
06/05/2008US20080128315 Resorbable Pouches for Implantable Medical Devices
06/05/2008US20080128314 Kit of two separately prepared components, the drug and the fat emulsion are combined on the occasion of use; paclitaxel or docetaxel; oleic acid or sodium oleate; polyethylene glycol, propylene glycol and ethanol; an oily component; injectable solution
06/05/2008DE60129697T2 Kondensierte azepinderivate und ihre verwendung als antidiuretisches mittel Condensed azepine derivatives and their use as antidiuretic agent
06/05/2008DE202006020222U1 Schnell zerfallende Darreichungsform umfassend Magnesiumcarbonat schwer Rapidly disintegrating dosage form comprising magnesium difficult
06/05/2008DE202005021512U1 Macrogol-Präparat Macrogol preparation
06/05/2008DE102006058183A1 Verwendung von Substanzen, die den zellulären Glutathion-Gehalt absenken, zur Herstellung eines Arzneimittels zur Behandlung von T-Zell vermittelten Autoimmunkrankheiten Use of substances which lower the cellular glutathione content, to prepare a medicament for the treatment of T cell mediated autoimmune diseases
06/05/2008DE102006056783A1 Zubereitung zur transdermalen Verabreichung von Galanthamin Preparation for transdermal administration of galanthamine
06/05/2008DE102006056740A1 Cyclisch substituierte 3,5-Dicyano-2-thiopyridine und ihre Verwendung Cyclic substituted 3,5-dicyano-2-thiopyridines and their use
06/05/2008DE102006056739A1 Substituierte 4-Amino-3,5-dicyano-2-thiopyridine und ihre Verwendung Substituted 4-amino-3,5-dicyano-2-thiopyridines, and their use
06/05/2008DE102006056697A1 Galanthamin-haltiges Arzneimittel mit kontrollierter Freisetzung Galanthamine-containing pharmaceutical controlled release
06/05/2008DE102006056558A1 Intraocular fluid, useful in eye surgery, e.g. during lens replacement for cataract treatment, contains blue light absorbing colorant to prevent damage to retina
06/05/2008CA2705495A1 Methods of diagnosing and alleviating gadolinium toxicity
06/05/2008CA2704280A1 Method of treatment and compositions of d-chiro inositol and phosphates thereof
06/05/2008CA2673483A1 Compositions of chk1 inhibitors
06/05/2008CA2673128A1 Compositions and methods for suppressing endometrial proliferation
06/05/2008CA2672936A1 Method for in situ solidification of blood-polymer compositions for regenerative medicine and cartilage repair applications
06/05/2008CA2672327A1 Aza-indolyl compounds and methods of use
06/05/2008CA2672273A1 Methods for the treatment of alcohol abuse, addiction and dependency
06/05/2008CA2671217A1 New a.beta. conformer selective anti-a.beta. globulomer monoclonal antibodies
06/05/2008CA2671169A1 Agent for the treatment of vascular leaks
06/05/2008CA2671081A1 Stabilized adhesive preparation containing donepezil
06/05/2008CA2671080A1 Carboxylic acid derivatives
06/05/2008CA2671075A1 Substituted estratrien derivatives as 17beta hsd inhibitors
06/05/2008CA2671006A1 Method for suppressing discoloration over time of adhesive preparation containing donepezil
06/05/2008CA2671000A1 Method for suppressing coloring of adhesive preparation containing donepezil and method for reducing amounts of donepezil-related substances formed
06/05/2008CA2670995A1 Stabilized adhesive preparation containing donepezil
06/05/2008CA2670991A1 Percutaneously absorbable preparation comprising donepezil
06/05/2008CA2670984A1 Novel curcumin derivative
06/05/2008CA2670976A1 Cyclic amine compound
06/05/2008CA2670966A1 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
06/05/2008CA2670957A1 Modulation of prostaglandin/cyclooxygenase metabolic pathways
06/05/2008CA2670955A1 Potentiation of erythropoietin (epo) action by membrane steroid receptor agonists
06/05/2008CA2670858A1 Salts of 3-(3-amino-2-(r)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
06/05/2008CA2670790A1 Polypeptides comprising fas activation and nkg2d-ligand domains
06/05/2008CA2670778A1 Use of indolyl-3-glyoxylic acid derivatives including indibulin, alone or in combination with further agents for treating cancer
06/05/2008CA2670776A1 Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
06/05/2008CA2670774A1 Substituted piperizines for the treatment of pain
06/05/2008CA2670773A1 6-alkoxyalkyl estradiol derivatives and methods of use
06/05/2008CA2670736A1 Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
06/05/2008CA2670638A1 Organic compounds
06/05/2008CA2670636A1 Heteroaryl amide derivatives
06/05/2008CA2670628A1 2-{[2-(substituted amino)ethyl]sulfonyl}ethyl n,n,n',n'-tetrakis(2 -chloroethyl)phosphorodiamidates
06/05/2008CA2670601A1 Ointment compositions comprising a vitamin d derivative
06/05/2008CA2670599A1 Benzoyl peroxyde comprising compositions, at least one naphtoic acid derivative and at least one compound of polyurethane polymer-type or derivatives thereof, and their use
06/05/2008CA2670595A1 (r)-5-methyl-4,5-dihydro-pyrazole-1,5-dicarboxylic acid 1-[(4-chlorophenyl)amide 5-{[2-fluoro-4-(2-oxo-2h-pyridin-1-yl)-phenyl)amide) as a fact or xa inhibitor
06/05/2008CA2670587A1 Assay
06/05/2008CA2670573A1 Diaminocyclohexane and diaminocyclopentane derivatives
06/05/2008CA2670544A1 Estrogen/ serm and estrogen/ progestin bi-layer tablets
06/05/2008CA2670531A1 Ace2 activator compounds and methods of use thereof
06/05/2008CA2670517A1 Medicament with controlled release containing galanthamine
06/05/2008CA2670498A1 Combination of iap inhibitors and flt3 inhibitors
06/05/2008CA2670440A1 Use of beta-lactamase
06/05/2008CA2670313A1 Polymorphic forms of deferasirox (icl670a)
06/05/2008CA2670168A1 Amino quinazolines derivatives wuth blood platelet reducing properties
06/05/2008CA2670166A1 Hydantoin derivatives used as mmp inhibitors
06/05/2008CA2670123A1 Substituted quinazolines
06/05/2008CA2670116A1 Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
06/05/2008CA2670105A1 Substituted dihydroimidazoles and their use in the treatment of tumors
06/05/2008CA2669815A1 Nanoparticulate formulations and methods for the making and use thereof
06/05/2008CA2669531A1 Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents
06/05/2008CA2669060A1 Piperidine compounds
06/05/2008CA2668811A1 Methods of treating cognitive impairment and dementia